CUPR

Business Context and Reporting Period

Company: Cuprina Holdings (Cayman) Limited (Ticker: CUPR)
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: A Singapore-based biomedical company developing and commercializing chronic wound care products (primarily Maggot Debridement Therapy under the MEDIFLY brand) and cosmeceuticals. The company operates as a holding company with primary operations in Singapore.
Recent Milestone: Completed an Initial Public Offering (IPO) in April 2025, raising approximately US$10.85 million in net proceeds.

Key Financial Metrics (Year Ended Dec 31, 2025)

Material Changes vs. Prior Period

• Revenue Growth: Revenue increased 3.3% year-over-year (YoY) to S$49,894, driven by increased patient volume for MEDIFLY products (96 patients in 2025 vs. 78 in 2024).
• Expense Surge: Operating expenses increased 194.1% YoY to S$4.83 million. This was primarily due to a 588.6% increase in "Other Operating Expenses" (S$3.67 million), driven by professional fees for corporate development, SEC/FINRA compliance, and Director & Officer (D&O) insurance following the IPO.
• Liquidity Position: Cash and cash equivalents increased significantly from S$116,472 in 2024 to S$3.12 million in 2025, largely due to IPO proceeds (S$17.6 million gross) offset by repayment of related party advances and deferred offering costs.
• Working Capital: The company moved from net current liabilities of S$4.38 million in 2024 to net current assets of S$4.22 million in 2025.

Guidance, Outlook, and Risks

Outlook and Strategy

• Product Pipeline: Developing bullfrog collagen sponge dressings (clinical trials expected late 2026) and iodine-based antiseptics via a new joint venture with Aiodine Laboratory Pte. Ltd.
• Geographic Expansion: Plans to expand into mainland China, Hong Kong, and the Middle East (GCC). Received product classification from Saudi Food and Drug Authority (SFDA) in March 2026 for MEDIFLY.
• Capital Needs: Management believes current cash reserves (approx. US$2.4 million) are sufficient for the next 12 months. Future funding may be required for R&D and expansion.

Key Risks and Contingencies

• Profitability: The company is an early-stage entity with a history of losses and no assurance of future profitability. Net losses increased significantly in 2025 due to public company compliance costs.
• Regulatory Approval: Success depends on obtaining FDA 510(k) clearance for MEDIFLY products (currently awaiting response to FDA request for additional information) and other pipeline products. Delays could materially harm the business.
• Intellectual Property: The primary revenue-generating product (MEDIFLY) has no patent protection and relies on trade secrets, exposing the company to competition from equivalent products.
• Internal Controls: A material weakness was identified regarding the lack of written sales agreements (orders often via WhatsApp). Management is implementing an automated ordering process expected to be operational by H2 2026.
• Customer Concentration: The top five customers accounted for 65.7% of revenue in 2025, with the largest single customer representing 28.3%.

Investor Verification Checklist

• Regulatory Status: Verify the status of the FDA 510(k) response submission and the timeline for clearance, as this is critical for US market entry.
• Internal Control Remediation: Confirm the implementation timeline and effectiveness of the new automated ordering system to address the identified material weakness.
• Related Party Transactions: Review the repayment terms and status of the S$2.93 million owed to related parties (primarily Cuprina Holding Pte. Ltd.) as of year-end.
• Product Pipeline Progress: Monitor the progress of ISO 10993 biocompatibility testing for bullfrog collagen products and the commercialization timeline for the Aiodine joint venture.
• Customer Retention: Assess the stability of the top five customers, given they represent over 65% of total revenue.